메뉴 건너뛰기




Volumn 9, Issue 4, 2008, Pages 523-535

Treatment options for non-motor symptoms in late-stage Parkinson's disease

Author keywords

Bone fractures; Dementia; Dysautonomia; Falls; Late stage Parkinson's disease; Pain; Psychosis

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; AMANTADINE; ANTIHYPERTENSIVE AGENT; ANTIPARKINSON AGENT; BACLOFEN; BENZODIAZEPINE; BOTULINUM TOXIN; BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT; CISAPRIDE; CLOZAPINE; DOMPERIDONE; DONEPEZIL; DOPAMINE DERIVATIVE; ERGOCALCIFEROL; ETILEFRINE; FLUDOCORTISONE; LEVODOPA; MACROGOL; MIDODRINE; MINERALOCORTICOID; PLACEBO; QUETIAPINE; RISEDRONIC ACID; RIVASTIGMINE; SELEGILINE; TEGASEROD; THREO 3,4 DIHYDROXYPHENYLSERINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; YOHIMBINE; BONE DENSITY CONSERVATION AGENT; CHOLINESTERASE INHIBITOR; GASTROINTESTINAL AGENT; NEUROLEPTIC AGENT; VASOCONSTRICTOR AGENT;

EID: 40649125791     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.4.523     Document Type: Review
Times cited : (24)

References (98)
  • 1
  • 2
    • 32544432029 scopus 로고    scopus 로고
    • Non-motor symptoms of Parkinson's disease: Diagnosis and management
    • Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006;5:235-45
    • (2006) Lancet Neurol , vol.5 , pp. 235-245
    • Chaudhuri, K.R.1    Healy, D.G.2    Schapira, A.H.3
  • 3
    • 0034719073 scopus 로고    scopus 로고
    • Complications and limitations of drug therapy for Parkinson's disease
    • Jankovic J. Complications and limitations of drug therapy for Parkinson's disease. Neurology 2000;55:S2-6
    • (2000) Neurology , vol.55
    • Jankovic, J.1
  • 4
    • 1942520420 scopus 로고    scopus 로고
    • Challenges in Parkinson's disease: Restoration of the nigrostriatal dopamine system is not enough
    • Lang AE, Obeso JA. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 2004;3:309-16
    • (2004) Lancet Neurol , vol.3 , pp. 309-316
    • Lang, A.E.1    Obeso, J.A.2
  • 5
    • 14944354884 scopus 로고    scopus 로고
    • Sydney Multicenter Study of Parkinson's disease: Non-L-dopa-responsive problems dominate at 15 years
    • Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20:190-9
    • (2005) Mov Disord , vol.20 , pp. 190-199
    • Hely, M.A.1    Morris, J.G.2    Reid, W.G.3    Trafficante, R.4
  • 6
    • 0014082977 scopus 로고
    • Parkinsonism: Onset, progression and mortality
    • Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42
    • (1967) Neurology , vol.17 , pp. 427-442
    • Hoehn, M.M.1    Yahr, M.D.2
  • 7
    • 4644321549 scopus 로고    scopus 로고
    • Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations
    • Goetz CG, Poewe W, Rascal O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 2004;19:1020-8
    • (2004) Mov Disord , vol.19 , pp. 1020-1028
    • Goetz, C.G.1    Poewe, W.2    Rascal, O.3
  • 8
    • 20544468414 scopus 로고    scopus 로고
    • Nonmotor complications in Parkinson's disease
    • Adler CH. Nonmotor complications in Parkinson's disease. Mov Disord 2005;20(Suppl 11):S23-9
    • (2005) Mov Disord , vol.20 , Issue.SUPPL. 11
    • Adler, C.H.1
  • 9
    • 0027302579 scopus 로고
    • Mortality from Parkinson's disease in England and Wales 1921-89
    • Clarke CE. Mortality from Parkinson's disease in England and Wales 1921-89. J Neurol Neurosurg Psychiatry 1993;56:690-3
    • (1993) J Neurol Neurosurg Psychiatry , vol.56 , pp. 690-693
    • Clarke, C.E.1
  • 10
    • 0031667288 scopus 로고    scopus 로고
    • The natural history of Parkinson's disease
    • Poewe WH, Wenning GK. The natural history of Parkinson's disease. Ann Neurol 1998;44:S1-9
    • (1998) Ann Neurol , vol.44
    • Poewe, W.H.1    Wenning, G.K.2
  • 11
    • 34548282615 scopus 로고    scopus 로고
    • Apomorphine in the treatment of Parkinson's disease
    • Menon R, Stacy M. Apomorphine in the treatment of Parkinson's disease. Expert Opin Pharmacother 2007;8:1941-50
    • (2007) Expert Opin Pharmacother , vol.8 , pp. 1941-1950
    • Menon, R.1    Stacy, M.2
  • 12
    • 34547191858 scopus 로고    scopus 로고
    • Medical management of levodopa-associated motor complications in patients with Parkinson's disease
    • Jankovic J, Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs 2007;21:677-92
    • (2007) CNS Drugs , vol.21 , pp. 677-692
    • Jankovic, J.1    Stacy, M.2
  • 14
    • 33845409358 scopus 로고    scopus 로고
    • Criteria for deep-brain stimulation in Parkinson's disease: Review and analysis
    • Moro E, Lang AE. Criteria for deep-brain stimulation in Parkinson's disease: review and analysis. Expert Rev Neurother 2006;6:1695-705
    • (2006) Expert Rev Neurother , vol.6 , pp. 1695-1705
    • Moro, E.1    Lang, A.E.2
  • 15
    • 34047239617 scopus 로고    scopus 로고
    • Duodenal levodopa infusion for the treatment of Parkinson's disease
    • Samanta J, Hauser RA. Duodenal levodopa infusion for the treatment of Parkinson's disease. Expert Opin Pharmacother 2007;8:657-64
    • (2007) Expert Opin Pharmacother , vol.8 , pp. 657-664
    • Samanta, J.1    Hauser, R.A.2
  • 16
    • 33646107153 scopus 로고    scopus 로고
    • Practice parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology
    • Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:996-1002
    • (2006) Neurology , vol.66 , pp. 996-1002
    • Miyasaki, J.M.1    Shannon, K.2    Voon, V.3
  • 17
    • 10044283107 scopus 로고    scopus 로고
    • Rivastigmine for dementia associated with Parkinson's disease
    • Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-18
    • (2004) N Engl J Med , vol.351 , pp. 2509-2518
    • Emre, M.1    Aarsland, D.2    Albanese, A.3
  • 18
    • 33646256562 scopus 로고    scopus 로고
    • Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: An active treatment extension study
    • Poewe W, Wolters E, Emre M, et al. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov Disord 2006;21:456-61
    • (2006) Mov Disord , vol.21 , pp. 456-461
    • Poewe, W.1    Wolters, E.2    Emre, M.3
  • 19
    • 21344444811 scopus 로고    scopus 로고
    • Donepezil for dementia in Parkinson's disease: A randomised, double blind, placebo controlled, crossover study
    • Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005;76:934-9
    • (2005) J Neurol Neurosurg Psychiatry , vol.76 , pp. 934-939
    • Ravina, B.1    Putt, M.2    Siderowf, A.3
  • 20
    • 0036265213 scopus 로고    scopus 로고
    • Donepezil for cognitive impairment in Parkinson's disease: A randomised controlled study
    • Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002;72:708-12
    • (2002) J Neurol Neurosurg Psychiatry , vol.72 , pp. 708-712
    • Aarsland, D.1    Laake, K.2    Larsen, J.P.3    Janvin, C.4
  • 21
    • 0842325101 scopus 로고    scopus 로고
    • Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease
    • Leroi I, Brandt J, Reich SG, et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 2004;19:1-8
    • (2004) Int J Geriatr Psychiatry , vol.19 , pp. 1-8
    • Leroi, I.1    Brandt, J.2    Reich, S.G.3
  • 22
    • 0034718471 scopus 로고    scopus 로고
    • Olanzapine and clozapine: Comparative effects on motor function in hallucinating Parkinson's disease patients
    • Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating Parkinson's disease patients. Neurology 2000;55:789-94
    • (2000) Neurology , vol.55 , pp. 789-794
    • Goetz, C.G.1    Blasucci, L.M.2    Leurgans, S.3    Pappert, E.J.4
  • 23
    • 0033709683 scopus 로고    scopus 로고
    • Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial
    • Mohr E, Mendis T, Hildebrand K, De Deyn PP. Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial. Mov Disord 2000;15:1230-7
    • (2000) Mov Disord , vol.15 , pp. 1230-1237
    • Mohr, E.1    Mendis, T.2    Hildebrand, K.3    De Deyn, P.P.4
  • 24
    • 0034022838 scopus 로고    scopus 로고
    • Risperidone treatment of drug-related psychosis in patients with parkinsonism
    • Leopold NA. Risperidone treatment of drug-related psychosis in patients with parkinsonism. Mov Disord 2000;15:301-4
    • (2000) Mov Disord , vol.15 , pp. 301-304
    • Leopold, N.A.1
  • 25
    • 33846116654 scopus 로고    scopus 로고
    • Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing
    • Schindehutte J, Trenkwalder C. Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing. Clin Neurol Neurosurg 2007;109:188-91
    • (2007) Clin Neurol Neurosurg , vol.109 , pp. 188-191
    • Schindehutte, J.1    Trenkwalder, C.2
  • 28
    • 33846447413 scopus 로고    scopus 로고
    • Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease
    • Friedman JH, Berman RM, Goetz CG, et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord 2006;21:2078-81
    • (2006) Mov Disord , vol.21 , pp. 2078-2081
    • Friedman, J.H.1    Berman, R.M.2    Goetz, C.G.3
  • 29
    • 1442300056 scopus 로고    scopus 로고
    • Aripiprazole for drug-induced psychosis in Parkinson disease: Preliminary experience
    • Fernandez HH, Trieschmann ME, Friedman JH. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol 2004;27:4-5
    • (2004) Clin Neuropharmacol , vol.27 , pp. 4-5
    • Fernandez, H.H.1    Trieschmann, M.E.2    Friedman, J.H.3
  • 30
    • 33750369930 scopus 로고    scopus 로고
    • Aripiprazole associated with severe exacerbation of Parkinson's disease
    • Wickremaratchi M, Morris HR, Ali IM. Aripiprazole associated with severe exacerbation of Parkinson's disease. Mov Disord 2006;21:1538-9
    • (2006) Mov Disord , vol.21 , pp. 1538-1539
    • Wickremaratchi, M.1    Morris, H.R.2    Ali, I.M.3
  • 31
    • 0033545542 scopus 로고    scopus 로고
    • Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease
    • The Parkinson Study Group
    • The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999;340:757-63
    • (1999) N Engl J Med , vol.340 , pp. 757-763
  • 32
    • 1942421734 scopus 로고    scopus 로고
    • Clozapine in drug induced psychosis in Parkinson's disease: A randomised, placebo controlled study with open follow up
    • Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004;75:689-95
    • (2004) J Neurol Neurosurg Psychiatry , vol.75 , pp. 689-695
    • Pollak, P.1    Tison, F.2    Rascol, O.3
  • 33
    • 33846074353 scopus 로고    scopus 로고
    • Clozapine-associated myocarditis: A review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003
    • Haas SJ, Hill R, Krum H, et al. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf 2007;30:47-57
    • (2007) Drug Saf , vol.30 , pp. 47-57
    • Haas, S.J.1    Hill, R.2    Krum, H.3
  • 34
    • 0033610722 scopus 로고    scopus 로고
    • Myocarditis and cardiomyopathy associated with clozapine
    • Killian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999;354:1841-5
    • (1999) Lancet , vol.354 , pp. 1841-1845
    • Killian, J.G.1    Kerr, K.2    Lawrence, C.3    Celermajer, D.S.4
  • 35
    • 11144267254 scopus 로고    scopus 로고
    • Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service
    • Reinders J, Parsonage W, Lange D, et al. Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service. Aust NZ J Psychiatry 2004;38:915-22
    • (2004) Aust NZ J Psychiatry , vol.38 , pp. 915-922
    • Reinders, J.1    Parsonage, W.2    Lange, D.3
  • 36
    • 3343000099 scopus 로고    scopus 로고
    • Clozapine-induced acute interstitial nephritis
    • Au AF, Luthra V, Stern R. Clozapine-induced acute interstitial nephritis. Am J Psychiatry 2004;161:1501
    • (2004) Am J Psychiatry , vol.161 , pp. 1501
    • Au, A.F.1    Luthra, V.2    Stern, R.3
  • 37
    • 0033517566 scopus 로고    scopus 로고
    • Clozapine-induced acute interstitial nephritis
    • Elias TJ, Bannister KM, Clarkson AR, et al. Clozapine-induced acute interstitial nephritis. Lancet 1999;354:1180-1
    • (1999) Lancet , vol.354 , pp. 1180-1181
    • Elias, T.J.1    Bannister, K.M.2    Clarkson, A.R.3
  • 38
    • 0343133914 scopus 로고    scopus 로고
    • Association of venous thromboembolism and clozapine
    • Hagg S, Spigset O, Soderstrom TG. Association of venous thromboembolism and clozapine. Lancet 2000;355:1155-6
    • (2000) Lancet , vol.355 , pp. 1155-1156
    • Hagg, S.1    Spigset, O.2    Soderstrom, T.G.3
  • 39
    • 26444597010 scopus 로고    scopus 로고
    • Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease
    • Ondo WG, Tintner R, Voung KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005;20:958-63
    • (2005) Mov Disord , vol.20 , pp. 958-963
    • Ondo, W.G.1    Tintner, R.2    Voung, K.D.3
  • 40
    • 34147140466 scopus 로고    scopus 로고
    • Effect of quetiapine in psychotic Parkinson's disease patients: A double-blind labeled study of 3 months' duration
    • Rabey JM, Prokhorov T, Miniovitz A, et al. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov Disord 2007;22:313-8
    • (2007) Mov Disord , vol.22 , pp. 313-318
    • Rabey, J.M.1    Prokhorov, T.2    Miniovitz, A.3
  • 41
    • 4043113047 scopus 로고    scopus 로고
    • Falls and freezing of gait in Parkinson's disease: A review of two interconnected, episodic phenomena
    • Bloem BR, Hausdorff JM, Visser JE, Giladi N. Falls and freezing of gait in Parkinson's disease: a review of two interconnected, episodic phenomena. Mov Disord 2004;19:871-84
    • (2004) Mov Disord , vol.19 , pp. 871-884
    • Bloem, B.R.1    Hausdorff, J.M.2    Visser, J.E.3    Giladi, N.4
  • 42
    • 0037018742 scopus 로고    scopus 로고
    • Treatment interventions for Parkinson's disease: An evidence based assessment
    • Rascol O, Goetz C, Koller W, et al. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 2002;359:1589-98
    • (2002) Lancet , vol.359 , pp. 1589-1598
    • Rascol, O.1    Goetz, C.2    Koller, W.3
  • 43
    • 0035225781 scopus 로고    scopus 로고
    • Physiotherapy for patients with Parkinson's disease: A comparison of techniques
    • CD002817
    • Deane KH, Jones D, Playford ED, et al. Physiotherapy for patients with Parkinson's disease: a comparison of techniques. Cochrane Database Syst Rev 2001:CD002817
    • (2001) Cochrane Database Syst Rev
    • Deane, K.H.1    Jones, D.2    Playford, E.D.3
  • 44
    • 33646104205 scopus 로고    scopus 로고
    • Practice parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology
    • Suchowersky O, Gronseth G, Perlmutter J, et al. Practice parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:976-82
    • (2006) Neurology , vol.66 , pp. 976-982
    • Suchowersky, O.1    Gronseth, G.2    Perlmutter, J.3
  • 45
    • 33846873850 scopus 로고    scopus 로고
    • Cueing training in the home improves gait-related mobility in Parkinson's disease: The RESCUE trial
    • Nieuwboer A, Kwakkel G, Rochester L, et al. Cueing training in the home improves gait-related mobility in Parkinson's disease: the RESCUE trial. J Neurol Neurosurg Psychiatry 2007;78:134-40
    • (2007) J Neurol Neurosurg Psychiatry , vol.78 , pp. 134-140
    • Nieuwboer, A.1    Kwakkel, G.2    Rochester, L.3
  • 46
    • 30644456332 scopus 로고    scopus 로고
    • Gait and step training to reduce falls in Parkinson's disease
    • Protas EJ, Mitchell K, Williams A, et al. Gait and step training to reduce falls in Parkinson's disease. NeuroRehabilitation 2005;20:183-90
    • (2005) NeuroRehabilitation , vol.20 , pp. 183-190
    • Protas, E.J.1    Mitchell, K.2    Williams, A.3
  • 48
    • 33746931673 scopus 로고    scopus 로고
    • 2 for prevention of hip fracture in Parkinson's disease: A randomized controlled trial
    • 2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial. Mov Disord 2006;21:924-9
    • (2006) Mov Disord , vol.21 , pp. 924-929
    • Sato, Y.1    Iwamoto, J.2    Kanoko, T.3    Satoh, K.4
  • 49
    • 34147108671 scopus 로고    scopus 로고
    • Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease
    • Sato Y, Honda Y, Iwamoto J. Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. Neurology 2007;68:911-5
    • (2007) Neurology , vol.68 , pp. 911-915
    • Sato, Y.1    Honda, Y.2    Iwamoto, J.3
  • 51
    • 33845187834 scopus 로고    scopus 로고
    • Joint and skeletal deformities in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy
    • Ashour R, Jankovic J. Joint and skeletal deformities in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Mov Disord 2006;21:1856-63
    • (2006) Mov Disord , vol.21 , pp. 1856-1863
    • Ashour, R.1    Jankovic, J.2
  • 52
    • 34548460736 scopus 로고    scopus 로고
    • The effect of duloxetine on primary pain symptoms in Parkinson disease
    • Djaldetti R, Yust-Katz S, Kolianov V, et al. The effect of duloxetine on primary pain symptoms in Parkinson disease. Clin Neuropharmacol 2007;30:201-5
    • (2007) Clin Neuropharmacol , vol.30 , pp. 201-205
    • Djaldetti, R.1    Yust-Katz, S.2    Kolianov, V.3
  • 53
    • 29244432154 scopus 로고    scopus 로고
    • Dias R, Cutts S, Massoud S. Frozen shoulder. BMJ 2005;331:1453-6
    • Dias R, Cutts S, Massoud S. Frozen shoulder. BMJ 2005;331:1453-6
  • 55
    • 29744440474 scopus 로고    scopus 로고
    • Drake DF, Harkins S, Qutubuddin A. Pain in Parkinson's disease: pathology to treatment, medication to deep brain stimulation. NeuroRehabilitation 2005;20:335-41
    • Drake DF, Harkins S, Qutubuddin A. Pain in Parkinson's disease: pathology to treatment, medication to deep brain stimulation. NeuroRehabilitation 2005;20:335-41
  • 57
    • 84882535310 scopus 로고    scopus 로고
    • Stocchi F. Gastrointestinal, urological. and sleep problems in Parkinson's disease. In: Principles of Treatment in Parkinson's Disease. Schapira AHV, Olanow CW, editors. Philadelphia: Butterworth Heinemann; 2005 p. 251-75
    • Stocchi F. Gastrointestinal, urological. and sleep problems in Parkinson's disease. In: Principles of Treatment in Parkinson's Disease. Schapira AHV, Olanow CW, editors. Philadelphia: Butterworth Heinemann; 2005 p. 251-75
  • 58
    • 0022575682 scopus 로고
    • Swallowing and speech production in Parkinson's disease
    • Robbins JA, Logemann JA, Kirshner HS. Swallowing and speech production in Parkinson's disease. Ann Neurol 1986;19:283-7
    • (1986) Ann Neurol , vol.19 , pp. 283-287
    • Robbins, J.A.1    Logemann, J.A.2    Kirshner, H.S.3
  • 59
    • 0036765130 scopus 로고    scopus 로고
    • Systematic review of paramedical therapies for Parkinson's disease
    • Deane KH, Ellis-Hill C, Jones D, et al. Systematic review of paramedical therapies for Parkinson's disease. Mov Disord 2002;17:984-91
    • (2002) Mov Disord , vol.17 , pp. 984-991
    • Deane, K.H.1    Ellis-Hill, C.2    Jones, D.3
  • 60
    • 0035221220 scopus 로고    scopus 로고
    • Non-pharmacological therapies for dysphagia in Parkinson's disease
    • CD002816
    • Deane KH, Whurr R, Clarke CE, et al. Non-pharmacological therapies for dysphagia in Parkinson's disease. Cochrane Database Syst Rev 2001:CD002816
    • (2001) Cochrane Database Syst Rev
    • Deane, K.H.1    Whurr, R.2    Clarke, C.E.3
  • 61
    • 33646925831 scopus 로고    scopus 로고
    • Botulinum toxin type A for drooling in Parkinson's disease: A double-blind, randomized, placebo-controlled study
    • Lagalla G, Millevolte M, Capecci M, et al. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2006;21:704-7
    • (2006) Mov Disord , vol.21 , pp. 704-707
    • Lagalla, G.1    Millevolte, M.2    Capecci, M.3
  • 62
    • 0242662829 scopus 로고    scopus 로고
    • A randomized trial of botulinum toxin A for treatment of drooling
    • Lipp A, Trottenberg T, Schink T, et al. A randomized trial of botulinum toxin A for treatment of drooling. Neurology 2003;61:1279-81
    • (2003) Neurology , vol.61 , pp. 1279-1281
    • Lipp, A.1    Trottenberg, T.2    Schink, T.3
  • 63
    • 0033974106 scopus 로고    scopus 로고
    • Botulinum toxin A as treatment for drooling saliva in PD
    • Pal PK, Calne DB, Calne S, Tsui JK. Botulinum toxin A as treatment for drooling saliva in PD. Neurology 2000;54:244-7
    • (2000) Neurology , vol.54 , pp. 244-247
    • Pal, P.K.1    Calne, D.B.2    Calne, S.3    Tsui, J.K.4
  • 64
    • 0032860868 scopus 로고    scopus 로고
    • Botulinum toxin is a useful treatment in excessive drooling in saliva
    • Bhatia KP, Munchau A, Brown P. Botulinum toxin is a useful treatment in excessive drooling in saliva. J Neurol Neurosurg Psychiatry 1999;67:697
    • (1999) J Neurol Neurosurg Psychiatry , vol.67 , pp. 697
    • Bhatia, K.P.1    Munchau, A.2    Brown, P.3
  • 65
    • 0000442521 scopus 로고    scopus 로고
    • Quantitative assessment of parkinsonian sialorrhea and results of treatment with botulinum toxin
    • Friedman A, Potulska A. Quantitative assessment of parkinsonian sialorrhea and results of treatment with botulinum toxin. Parkinsonism Relat Disord 2001;7:329-32
    • (2001) Parkinsonism Relat Disord , vol.7 , pp. 329-332
    • Friedman, A.1    Potulska, A.2
  • 66
    • 1542315511 scopus 로고    scopus 로고
    • Ultrasound-guided versus 'blind' intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson's disease
    • Dogu O, Apaydin D, Sevim S, et al. Ultrasound-guided versus 'blind' intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson's disease. Clin Neurol Neurosurg 2004;106:93-6
    • (2004) Clin Neurol Neurosurg , vol.106 , pp. 93-96
    • Dogu, O.1    Apaydin, D.2    Sevim, S.3
  • 67
    • 0345830743 scopus 로고    scopus 로고
    • A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease
    • Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology 2004;62:37-40
    • (2004) Neurology , vol.62 , pp. 37-40
    • Ondo, W.G.1    Hunter, C.2    Moore, W.3
  • 68
    • 38049053597 scopus 로고    scopus 로고
    • Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease
    • Thomsen TR, Galpern WR, Asante A, et al. Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease. Mov Disord 2007;22:2268-73
    • (2007) Mov Disord , vol.22 , pp. 2268-2273
    • Thomsen, T.R.1    Galpern, W.R.2    Asante, A.3
  • 69
    • 33846811509 scopus 로고    scopus 로고
    • Tegaserod in constipation associated with Parkinson disease
    • Morgan JC, Sethi KD. Tegaserod in constipation associated with Parkinson disease. Clin Neuropharmacol 2007;30:52-4
    • (2007) Clin Neuropharmacol , vol.30 , pp. 52-54
    • Morgan, J.C.1    Sethi, K.D.2
  • 70
    • 34548272597 scopus 로고    scopus 로고
    • Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study
    • Zangaglia R, Martignoni E, Glorioso M, et al. Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study. Mov Disord 2007;22:1239-44
    • (2007) Mov Disord , vol.22 , pp. 1239-1244
    • Zangaglia, R.1    Martignoni, E.2    Glorioso, M.3
  • 71
    • 33745847810 scopus 로고    scopus 로고
    • Bladder dysfunction in parkinsonism: Mechanisms, prevalence, symptoms, and management
    • Winge K, Fowler CJ. Bladder dysfunction in parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord 2006;21:737-45
    • (2006) Mov Disord , vol.21 , pp. 737-745
    • Winge, K.1    Fowler, C.J.2
  • 72
    • 41149107709 scopus 로고    scopus 로고
    • Depression, psychosis, and cognitive dysfunction in Parkinson's disease
    • Schapira AHV, Olanow CW, editors. Philadelphia Butterworth Heinemann;
    • Stocchi F. Depression, psychosis, and cognitive dysfunction in Parkinson's disease. In: Principles of Treatment in Parkinson's Disease. Schapira AHV, Olanow CW, editors. Philadelphia Butterworth Heinemann; 2005 p. 237-50
    • (2005) Principles of Treatment in Parkinson's Disease , pp. 237-250
    • Stocchi, F.1
  • 73
    • 20444470602 scopus 로고    scopus 로고
    • Striatal deformities of the hand and foot in Parkinson's disease
    • Ashour R, Tintner R, Jankovic J. Striatal deformities of the hand and foot in Parkinson's disease. Lancet Neurol 2005;4:423-31
    • (2005) Lancet Neurol , vol.4 , pp. 423-431
    • Ashour, R.1    Tintner, R.2    Jankovic, J.3
  • 74
    • 0017681987 scopus 로고
    • Neurosurgical treatment of the dyskinesias
    • Cooper IS. Neurosurgical treatment of the dyskinesias. Clin Neurosurg 1977;24:367-90
    • (1977) Clin Neurosurg , vol.24 , pp. 367-390
    • Cooper, I.S.1
  • 75
    • 23244440135 scopus 로고    scopus 로고
    • Camptocormia: Pathogenesis, classification, and response to therapy
    • Azher SN, Jankovic J. Camptocormia: pathogenesis, classification, and response to therapy. Neurology 2005;65:355-9
    • (2005) Neurology , vol.65 , pp. 355-359
    • Azher, S.N.1    Jankovic, J.2
  • 76
    • 0342699486 scopus 로고    scopus 로고
    • Relation between cholinesterase inhibitor and Pisa syndrome
    • Kwak YT, Han IW, Baik J, Koo MS. Relation between cholinesterase inhibitor and Pisa syndrome. Lancet 2000;355:2222
    • (2000) Lancet , vol.355 , pp. 2222
    • Kwak, Y.T.1    Han, I.W.2    Baik, J.3    Koo, M.S.4
  • 77
    • 34848861380 scopus 로고    scopus 로고
    • Levodopa raises objective pain threshold in Parkinson's disease: A RIII reflex study
    • Gerdelat-Mas A, Simonetta-Moreau M, Thalamas C, et al. Levodopa raises objective pain threshold in Parkinson's disease: a RIII reflex study. J Neurol Neurosurg Psychiatry 2007;78:1140-2
    • (2007) J Neurol Neurosurg Psychiatry , vol.78 , pp. 1140-1142
    • Gerdelat-Mas, A.1    Simonetta-Moreau, M.2    Thalamas, C.3
  • 79
    • 0037334135 scopus 로고    scopus 로고
    • Intraarticular corticosteroids, supervised physiotherapy, or a combination of the two in the treatment of adhesive capsulitis of the shoulder: A placebo-controlled trial
    • Carette S, Moffet H, Tardif J, et al. Intraarticular corticosteroids, supervised physiotherapy, or a combination of the two in the treatment of adhesive capsulitis of the shoulder: a placebo-controlled trial. Arthritis Rheum 2003;48:829-38
    • (2003) Arthritis Rheum , vol.48 , pp. 829-838
    • Carette, S.1    Moffet, H.2    Tardif, J.3
  • 80
    • 0032494807 scopus 로고    scopus 로고
    • Effectiveness of corticosteroid injections versus physiotherapy for treatment of painful stiff shoulder in primary care: Randomised trial
    • Van Der Windt DA, Koes BW, Deville W, et al. Effectiveness of corticosteroid injections versus physiotherapy for treatment of painful stiff shoulder in primary care: randomised trial. BMJ 1998;317:1292-6
    • (1998) BMJ , vol.317 , pp. 1292-1296
    • Van Der Windt, D.A.1    Koes, B.W.2    Deville, W.3
  • 81
    • 33747865174 scopus 로고    scopus 로고
    • EFNS guidelines on the diagnosis and management of orthostatic hypotension
    • Lahrmann H, Cortelli P, Hilz M, et al. EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol 2006;13:930-6
    • (2006) Eur J Neurol , vol.13 , pp. 930-936
    • Lahrmann, H.1    Cortelli, P.2    Hilz, M.3
  • 82
    • 12544257720 scopus 로고    scopus 로고
    • Guidelines on management (diagnosis and treatment) of syncope - update 2004
    • Brignole M, Alboni P, Benditt DG, et al. Guidelines on management (diagnosis and treatment) of syncope - update 2004. Europace 2004;6:467-537
    • (2004) Europace , vol.6 , pp. 467-537
    • Brignole, M.1    Alboni, P.2    Benditt, D.G.3
  • 83
    • 34748866218 scopus 로고    scopus 로고
    • Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease
    • Schoffer KL, Henderson RD, O'Maley K, O'Sullivan JD. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. Mov Disord 2007;22:1543-9
    • (2007) Mov Disord , vol.22 , pp. 1543-1549
    • Schoffer, K.L.1    Henderson, R.D.2    O'Maley, K.3    O'Sullivan, J.D.4
  • 84
    • 0037180460 scopus 로고    scopus 로고
    • Water drinking acutely improves orthostatic tolerance in healthy subjects
    • Schroeder C, Bush VE, Norcliffe LJ, et al. Water drinking acutely improves orthostatic tolerance in healthy subjects. Circulation 2002;106:2806-11
    • (2002) Circulation , vol.106 , pp. 2806-2811
    • Schroeder, C.1    Bush, V.E.2    Norcliffe, L.J.3
  • 85
    • 0033608269 scopus 로고    scopus 로고
    • A potent pressor response elicited by drinking water
    • Jordan J, Shannon JR, Grogan E, et al. A potent pressor response elicited by drinking water. Lancet 1999;353:723
    • (1999) Lancet , vol.353 , pp. 723
    • Jordan, J.1    Shannon, J.R.2    Grogan, E.3
  • 86
    • 33645931324 scopus 로고    scopus 로고
    • The patient with supine hypertension and orthostatic hypotension: A clinical dilemma
    • Naschitz JE, Slobodin G, Elias N, Rosner I. The patient with supine hypertension and orthostatic hypotension: a clinical dilemma. Poatgrad Med J 2006;82:246-53
    • Poatgrad Med , vol.J 2006 , Issue.82 , pp. 246-253
    • Naschitz, J.E.1    Slobodin, G.2    Elias, N.3    Rosner, I.4
  • 87
    • 0142219814 scopus 로고    scopus 로고
    • Dysautonomia in Parkinson's disease: Neurocardiological abnormalities
    • Goldstein DS. Dysautonomia in Parkinson's disease: neurocardiological abnormalities. Lancet Neurol 2003;2:669-76
    • (2003) Lancet Neurol , vol.2 , pp. 669-676
    • Goldstein, D.S.1
  • 88
    • 33645739276 scopus 로고    scopus 로고
    • Pyridostigmine treatment trial in neurogenic orthostatic hypotension
    • Singer W, Sandroni P, Opfer-Gehrking TL, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol 2006;63:513-8
    • (2006) Arch Neurol , vol.63 , pp. 513-518
    • Singer, W.1    Sandroni, P.2    Opfer-Gehrking, T.L.3
  • 89
    • 0024435720 scopus 로고
    • Swallowing abnormalities and their response to treatment in Parkinson's disease
    • Bushmann M, Dobmeyer SM, Leeker L, Perlmutter JS. Swallowing abnormalities and their response to treatment in Parkinson's disease. Neurology 1989;39:1309-14
    • (1989) Neurology , vol.39 , pp. 1309-1314
    • Bushmann, M.1    Dobmeyer, S.M.2    Leeker, L.3    Perlmutter, J.S.4
  • 91
    • 0017809747 scopus 로고
    • Evidence for a change in neurotransmitter affecting oesophageal motility in Parkinson's disease
    • Bramble MG, Cunliffe J, Dellipiani AW. Evidence for a change in neurotransmitter affecting oesophageal motility in Parkinson's disease. J Neurol Neurosurg Psychiatry 1978;41:709-12
    • (1978) J Neurol Neurosurg Psychiatry , vol.41 , pp. 709-712
    • Bramble, M.G.1    Cunliffe, J.2    Dellipiani, A.W.3
  • 92
    • 0024497156 scopus 로고
    • Off-period belching due to a reversible disturbance of oesophageal motility in Parkinson's disease and its treatment with apomorphine
    • Kempster PA, Lees AJ, Crichton P, et al. Off-period belching due to a reversible disturbance of oesophageal motility in Parkinson's disease and its treatment with apomorphine. Mov Disord 1989;4:47-52
    • (1989) Mov Disord , vol.4 , pp. 47-52
    • Kempster, P.A.1    Lees, A.J.2    Crichton, P.3
  • 93
    • 0018819764 scopus 로고
    • Interaction of levodopa and metoclopramide on gastric emptying
    • Berkowitz DM, McCallum RW. Interaction of levodopa and metoclopramide on gastric emptying. Clin Pharmacol Ther 1980;27:414-20
    • (1980) Clin Pharmacol Ther , vol.27 , pp. 414-420
    • Berkowitz, D.M.1    McCallum, R.W.2
  • 94
    • 0015374287 scopus 로고
    • The effect of antacid administration on the absorption and metabolism of levodopa
    • Leon AS, Spiegel HE. The effect of antacid administration on the absorption and metabolism of levodopa. J Clin Pharmacol New Drugs 1972;12:263-7
    • (1972) J Clin Pharmacol New Drugs , vol.12 , pp. 263-267
    • Leon, A.S.1    Spiegel, H.E.2
  • 96
    • 0026688256 scopus 로고
    • Clinical and pharmacokinetic effects of a diet rich in insoluble fiber on Parkinson disease
    • Astarloa R, Mena MA, Sanchez V, et al. Clinical and pharmacokinetic effects of a diet rich in insoluble fiber on Parkinson disease. Clin Neuropharmacol 1992;15:375-80
    • (1992) Clin Neuropharmacol , vol.15 , pp. 375-380
    • Astarloa, R.1    Mena, M.A.2    Sanchez, V.3
  • 97
    • 0024416844 scopus 로고
    • Anal sphincter dysfunction in Parkinson's disease
    • Mathers SE, Kempster PA, Law PJ, et al. Anal sphincter dysfunction in Parkinson's disease. Arch Neurol 1989;46:1061-4
    • (1989) Arch Neurol , vol.46 , pp. 1061-1064
    • Mathers, S.E.1    Kempster, P.A.2    Law, P.J.3
  • 98
    • 0024207550 scopus 로고
    • Role of subcutaneous apomorphine in parkinsonian voiding dysfunction
    • Christmas TJ, Kempster PA, Chapple CR, et al. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet 1988;2:1451-3
    • (1988) Lancet , vol.2 , pp. 1451-1453
    • Christmas, T.J.1    Kempster, P.A.2    Chapple, C.R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.